Benign Prostatic Hyperplasia and Lower Urinary Tract Symptoms
Baseline Factors as Predictors of Clinical Progression of Benign Prostatic Hyperplasia in Men Treated With Placebo
Crawford ED, et al. J Urol. 2006;175:1422-1426.
The Correlation Between Metabolic Syndrome and Prostatic Diseases
De Nunzio C, et al. Eur Urol. 2012;61:560-570.
A Systematic Review and Meta-analysis on the Use of Phosphodiesterase 5 Inhibitors Alone or in Combination with α-Blockers for Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia
Gacci M, et al. Eur Urol. 2012;61:994-1003.
The Mechanism of Action of Phosphodiesterase Type 5 Inhibitors in the Treatment of Lower Urinary Tract Symptoms Related to Benign Prostatic Hyperplasia
Giuliano F, et al. Eur Urol. 2013;63:506-516.
Laborde EE, McVary KT. Rev Urol. 2009;11(suppl 1):S19-S25.
Roehrborn CG. Rev Urol. 2009;11(suppl 1):S1-S8.
The Effect of Benign Lower Urinary Tract Symptoms on Subsequent Prostate Cancer Testing and Diagnosis
Weight CJ, et al. Eur Urol. 2013;63:1021-1027.
A practical guide to the evaluation and treatment of male lower urinary tract symptoms in the primary care setting
Rosenberg MT, et al. Int J Clin Pract. 2007;61:1535-1546.
Scientific and Clinical Insights Into Benign Prostatic Hyperplasia and Lower Urinary Tract Symptoms
Steven A. Kaplan, MD